What Is Cribriform Prostate Cancer?
Cribriform prostate cancer is a word pathologists use to describe how prostate cancer cells look under the microscope. The cells form large, sieve-like groups with tiny holes inside them. It is not a separate disease by itself. Instead, it is a growth pattern that can appear within prostate cancer, and it matters because it is linked to a higher risk of aggressive behavior than prostate cancers without this pattern.
Why does cribriform matter?
Not all prostate cancers behave the same way. Some grow very slowly and may be safely watched. Others are more likely to spread. When a pathology report shows cribriform pattern, doctors take it seriously because it has been associated with a greater chance of metastasis and recurrence.
In simple terms, cribriform is a sign that the cancer may be less favorable than the Gleason score alone might suggest.
What did the recent JAMA Oncology study show?
A 2025 secondary analysis of the randomized PROTECT trial looked at 15-year outcomes in men with localized prostate cancer and compared those with cribriform-positive disease to those with cribriform-negative disease. In this study, “cribriform-positive” included men whose biopsy showed invasive cribriform carcinoma and/or intraductal carcinoma.
The findings were important:
Among men with cribriform-positive prostate cancer, the 15-year risk of metastasis was 25% with active monitoring, 26% with surgery, and 8% with radiotherapy plus short-term hormone therapy.
Among men with cribriform-negative disease, the metastasis rates were much lower: 7% with active monitoring, 4% with surgery, and 3% with radiotherapy.
Overall, cribriform-positive disease was linked to a significantly higher risk of metastasis, while outcomes for cribriform-negative disease were favorable across treatment groups.
The takeaway is that cribriform-positive prostate cancer should not be treated as routine low-risk disease.
Does cribriform mean the cancer is high risk?
Not automatically, but it does raise concern.
Cribriform is usually considered an unfavorable feature. It may push doctors away from active surveillance and toward treatment, especially when it appears along with Gleason pattern 4, higher PSA, or suspicious imaging findings. Reviews in the medical literature note that cribriform architecture and intraductal carcinoma are associated with a higher risk of metastasis and prostate cancer death.
Can cribriform be missed?
Yes. Like many pathology findings, it can sometimes be missed on biopsy because a biopsy samples only part of the prostate. That is one reason second opinions on pathology from an expert center can be helpful in some cases. Research also suggests these patterns are not always easy to detect on biopsy or MRI.
What should patients ask their doctor?
If your pathology report mentions cribriform, good questions include:
Is the cribriform pattern definitely present?
Is there also intraductal carcinoma?
Does this change whether active surveillance is appropriate?
Should my biopsy slides be reviewed by an expert genitourinary pathologist?
Do I need additional imaging, such as MRI or PSMA PET, based on my overall risk?
Bottom line
Cribriform is an important pathology finding in prostate cancer. It does not mean every man has the same outlook, but it is a warning sign that the cancer may be more aggressive and may deserve closer evaluation and, in many cases, more active treatment. The recent PROTECT trial analysis strengthens that message by showing a much higher long-term metastasis risk in men with cribriform-positive disease.